Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric/gastroesophageal junction cancer treatment: A systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, S. | - |
dc.contributor.author | Kim, E. | - |
dc.contributor.author | Lee, H. | - |
dc.date.accessioned | 2021-09-17T06:40:17Z | - |
dc.date.available | 2021-09-17T06:40:17Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/49479 | - |
dc.description.abstract | Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have demonstrated varying effectiveness in treating esophageal or gastric/gastroesophageal junction (G/GEJ) cancer. Hence, this systematic review and meta-analysis evaluated the efficacy and safety of anti-PD-1/PD- L1 treatment in patients with esophageal or G/GEJ cancer by analyzing the types of medications. Randomized controlled trials comparing anti-PD-1/PD-L1 to control therapy were identified by searching PubMed, EMBASE, and ClinicalTrials.gov. The outcomes included overall survival (OS), progression-free survival (PFS) rates, and serious adverse events (SAEs), evaluating the differences in therapy types, including a comparison between PD-1 and PD-L1 inhibitors. Eight studies were included in the analysis. PD-1/PD-L1 inhibitors affected the overall OS rate increment without influencing the PFS rate (HR, 0.837; 95% CI, 0.753–0.929; p = 0.001; HR 0.991; 95% CI, 0.778–1.263; p = 0.942, respectively). Anti-PD-1 was significantly more beneficial for increasing OS and PFS than PD-L1 inhibitors. Anti-PD-1 and PD-L1 use was not significantly associated with SAE development in esophageal or G/GEJ cancer patients. PD-1/PD-L1 inhibitor use was associated with improved OS and PFS rate increase among PD-1 and PD-L1 inhibitors. Considering response variations to anti-PD-1/PD-L1 usage, more individualized treatments should be introduced in clinical practice. © 2021 by the authors. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric/gastroesophageal junction cancer treatment: A systematic review and meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/jcm10163612 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.10, no.16 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000689196900001 | - |
dc.identifier.scopusid | 2-s2.0-85112422939 | - |
dc.citation.number | 16 | - |
dc.citation.title | Journal of Clinical Medicine | - |
dc.citation.volume | 10 | - |
dc.type.docType | Review | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Gastric esophageal cancer | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | PD-1/PD-L1 inhibitor | - |
dc.subject.keywordPlus | GASTROESOPHAGEAL JUNCTION | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.